Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group plc has filed an Amendment No. 4 to its Schedule 13G, reporting a 0.8% beneficial ownership stake in OMNIAB, Inc. as of June 30, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing a 4.0% beneficial ownership stake in Entrada Therapeutics, Inc. as of June 30, 2025.

Janus Henderson Group plc reported a 4.5% passive ownership stake in The Beauty Health Company, holding 5,718,565 common shares as of June 30, 2025.

Janus Henderson Group plc has filed an Amendment No. 7 to its Schedule 13G, disclosing a 4.6% beneficial ownership stake in Walker & Dunlop, Inc. as of June 30, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Biohaven Ltd. common stock.

Janus Henderson Group plc has reported a 5.2% beneficial ownership stake in Dayforce, Inc., holding over 8.3 million shares.

Janus Henderson Group plc has reported a 6.1% beneficial ownership stake in Revvity, Inc., holding over 7.2 million American Depositary Shares.

Janus Henderson Group plc has increased its beneficial ownership in Dyne Therapeutics Inc. to 10.1% of common stock, holding 14,394,999 shares.

Janus Henderson Group PLC has increased its beneficial ownership in Avidity Biosciences, Inc. to 10.1% of common stock.

Janus Henderson Group plc has reported an increased beneficial ownership of 12.8% in Travere Therapeutics, Inc., holding over 11.3 million shares.

Janus Henderson Group plc and its affiliate, Janus Henderson Contrarian Fund, have reported an increased beneficial ownership in Surgery Partners, Inc., holding an aggregate of 12,954,916 shares, representing 10.1% of the common stock as of June 30, 2025.

Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 11.3% in Praxis Precision Medicines, Inc.'s common stock.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 10.1% beneficial ownership stake in Lantheus Holdings, Inc. common stock as of May 30, 2025.

Investment giant Janus Henderson Group plc has reported a 10.3% beneficial ownership stake in Mirum Pharmaceuticals, Inc., as detailed in its latest Schedule 13G Amendment No. 5 filing with the SEC.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has disclosed a passive beneficial ownership of 4.999% in Janus Henderson Group plc, having briefly exceeded 5% before reducing their stake.

Janus Henderson Group PLC has filed an Amendment No. 4 to its Schedule 13G, disclosing a beneficial ownership of 9.7% in Mirum Pharmaceuticals, Inc. as of March 31, 2025.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a combined beneficial ownership of 14.3% in Mereo BioPharma Group PLC's American Depositary Shares as of March 31, 2025.

Janus Henderson Group plc has filed an Amendment No. 4 to its Schedule 13G, updating its beneficial ownership in Teleflex Incorporated to 9.7% of common stock as of March 31, 2025.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a passive beneficial ownership of 9.9% in Tenax Therapeutics, Inc. through an amended Schedule 13G filing.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a 9.9% beneficial ownership stake in Forte Biosciences, Inc., as detailed in an amended Schedule 13G filing.

Janus Henderson Group plc and its affiliates have reported an increased beneficial ownership stake of 11.4% in Benitec Biopharma Inc. common stock as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a 6.6% beneficial ownership stake in Sensata Technologies Holding PLC as of March 31, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 7.5% beneficial ownership stake in Structure Therapeutics Inc. as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a 6.6% beneficial ownership stake in Omniab, Inc. as of March 31, 2025.

Janus Henderson Group PLC has filed an Amendment No. 7 to its Schedule 13G, disclosing a 5.3% beneficial ownership stake in Ligand Pharmaceuticals Incorporated as of March 31, 2025.

Janus Henderson Group plc has filed an Amendment No. 10 to its Schedule 13G, disclosing a passive beneficial ownership of 5.4% in Sensient Technologies Corporation as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a beneficial ownership of 5.4% of Rentokil Initial PLC's common stock as of March 31, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in Walker & Dunlop, Inc., held for investment purposes.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing its beneficial ownership of 5.5% of Revolution Medicines, Inc.'s common stock as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Edgewise Therapeutics, Inc. as of March 31, 2025.